leishmaniasis

File:Leishmaniasis ulcer.jpg

The symptoms of leishmaniasis are skin sores which erupt weeks to months after the person is bitten by infected sandflies.

Leishmaniasis may be divided into the following types:{{cite book| first1 = William D | last1 = James | first2 = Timothy G | last2 = Berger | first3 = Dirk M | last3 = Elston |title=Andrews' Diseases of the Skin: clinical Dermatology |publisher=Saunders Elsevier |year=2006 |pages=422–428 |isbn=978-0-7216-2921-6 }}

• Cutaneous leishmaniasis is the most common form, which causes an open sore at each bite site, which heals in a few months to a year and a half, leaving an unpleasant-looking scar.
• Diffuse cutaneous leishmaniasis produces widespread skin lesions which resemble leprosy, and may not heal on their own.

• Mucocutaneous leishmaniasis causes both skin and mucosal ulcers with damage primarily of the nose and mouth.
• Visceral leishmaniasis or kala-azar ('black fever') is the most serious form and is generally fatal if untreated. Other consequences, which can occur a few months to years after infection, include fever, damage to the spleen and liver, and anemia.

Leishmaniasis is considered one of the classic causes of a markedly enlarged (and therefore palpable) spleen; the organ, which is not normally felt during the examination of the abdomen, may even become larger than the liver in severe cases.{{citation needed|date=May 2021}}

File:Leishmaniasis life cycle diagram en.svg

Leishmaniasis is transmitted by the bite of infected female phlebotomine sandflies which can transmit the protozoa Leishmania. The sandflies inject the infective stage, metacyclic promastigotes, during blood meals. Metacyclic promastigotes in the puncture wound are phagocytized by macrophages, and transform into amastigotes. Amastigotes multiply in infected cells and affect different tissues, depending in part on the host, and in part on which Leishmania species is involved. These differing tissue specificities cause the differing clinical manifestations of the various forms of leishmaniasis. Sandflies become infected during blood meals on infected hosts when they ingest macrophages infected with amastigotes. In the sandfly's midgut, the parasites differentiate into promastigotes, which multiply, differentiate into metacyclic promastigotes, and migrate to the proboscis.

The genomes of three Leishmania species (L. major, L. infantum, and L. braziliensis) have been sequenced, and this has provided much information about the biology of the parasite. For example, in Leishmania, protein-coding genes are understood to be organized as large polycistronic units in a head-to-head or tail-to-tail manner; RNA polymerase II transcribes long polycistronic messages in the absence of defined RNA pol II promoters, and Leishmania has unique features concerning the regulation of gene expression in response to changes in the environment. The new knowledge from these studies may help identify new targets for urgently needed drugs and aid the development of vaccines.

Although most of the literature mentions only one genus transmitting Leishmania to humans (Lutzomyia) in the New World, a 2003 study by Galati suggested a new classification for New World sand flies, elevating several subgenera to the genus level. Elsewhere in the world, the genus Phlebotomus is considered the vector of leishmaniasis.{{cite book | first1 = Peter J | last1 = Myler | first2 = Nicolas | last2 = Fasel |title=Leishmania: After The Genome |publisher=Caister Academic Press |year=2008 |url=http://www.horizonpress.com/leish |isbn=978-1-904455-28-8 |url-status=live |archive-url=https://web.archive.org/web/20080423224948/http://www.horizonpress.com/leish |archive-date=23 April 2008 |df=dmy-all }}{{Page needed|date=September 2010}}

Some cases of infection of non-human animals of human-infecting species of Leishmania have been observed. In one study, L. major was identified in twelve out of ninety-one wild western lowland gorilla fecal samples{{cite journal

|title=Wild Gorillas as a Potential Reservoir of Leishmania major

|journal=J. Infect. Dis.

|volume=211

|number=2

|pages=267–273

|date=2015-01-15

|url=https://academic.oup.com/jid/article/211/2/267/860822

|doi=10.1093/infdis/jiu380

|first1=Ibrahim |last1=Hamad

|first2=Claire-Lise |last2=Forestier

|first3=Martine |last3=Peeters

|first4=Eric |last4=Delaporte

|first5=Didier |last5=Raoult

|first6=Fadi |last6=Bittar|pmid=25001460

|pmc=4342692

}}

and in a study of fifty-two captive non-human primates under zoo captivity in a leishmaniasis endemic area, eight (all three chimpanzees, three golden lion tamarins, a tufted capuchin, and an Angolan talapoin), were found to be infected with L. infantum and capable of infecting Lutzomyia longipalpis sand flies, although "parasite loads in infected sand flies observed in this study were considered low".{{cite journal

|title=Competence of non-human primates to transmit Leishmania infantum to the invertebrate vector Lutzomyia longipalpis

|doi=10.1371/journal.pntd.0007313

|date=2019-04-17

|journal=PLOS Neglected Tropical Diseases

|author1=Ayisa Rodrigues de Oliveira

|author2=Guilherme Rafael Gomide Pinheiro

|author3=Herlandes P. Tinoco

|author4=Maria Elvira Loyola

|author5=Carlyle Mendes Coelho

|author6=Edelberto Santos Dias

|author7=Érika Michalsky Monteiro

|author8=Fabiana de Oliveira Lara e Silva

|author9=Angela Tinoco Pessanha

|author10=Andreza Geisiane Maia Souza

|author11=Nathália Cristina Lima Pereira

|author12=Nelder F. Gontijo

|author13=Ricardo T. Fujiwara

|author14=Tatiane Alves da Paixão

|author15=Renato Lima Santos | volume=13 | issue=4 | pages=e0007313 | pmid=30995227 | pmc=6488095 |doi-access=free

}}

Visceral disease is usually caused by Leishmania donovani, L. infantum, or L. chagasi, but occasionally these species may cause other forms of disease. The cutaneous form of the disease is caused by more than 15 species of Leishmania.

Risk factors include malnutrition, deforestation, lack of sanitation, suppressed immune system, and urbanization.

• Socioeconomic conditions: Poor living conditions like overcrowded housing and inadequate sanitation are associated with increased human exposure to sandflies. Poor waste management and open sewage create ideal breeding grounds for sandflies in rural and low-income urban areas. Limited access to healthcare may delay diagnosis and treatment, which can contribute to more severe disease outcomes. Poor individuals may face a financial barrier to treatment, increasing their risk of severe disease.{{Cite journal |last1=Okwor |first1=Ifeoma |last2=Uzonna |first2=Jude |date=2016-03-02 |title=Social and Economic Burden of Human Leishmaniasis |url=https://www.ajtmh.org/view/journals/tpmd/94/3/article-p489.xml |journal=The American Journal of Tropical Medicine and Hygiene |language=EN |volume=94 |issue=3 |pages=489–493 |doi=10.4269/ajtmh.15-0408 |issn=0002-9637 |pmc=4775878 |pmid=26787156}}

• Malnutrition: Deficiencies in protein, iron, vitamin A, and zinc weaken the immune system, making it harder to fight Leishmania infections. This increases the risk of both cutaneous and visceral leishmaniasis, leading to more severe illness and poor treatment outcomes.{{cite journal |last1=Sacramento |first1=Laís Amorim |title=Malnutrition disrupts adaptive immunity during visceral leishmaniasis by enhancing IL-10 production |date=2024 |journal=PLOS Pathogens |volume=20 |issue=11 |doi=10.1371/journal.ppat.1012716 |pmc=11581394 |pmid=39527629 |last2=Lombana |first2=Claudia |last3=Scott |first3=Phillip|pages=e1012716 |doi-access=free }}

• Population Mobility: Migration and displacement due to conflict, economic hardship, or environmental changes contribute to the spread of leishmaniasis, particularly when non-immune individuals enter endemic areas. Refugees and seasonal agricultural workers are at higher risk due to limited access to vector control measures. Human activity in previously uninhabited lands may increase exposure to infected sandflies and wildfire reservoirs.{{Cite journal |last1=Wilke |first1=André B. B. |last2=Farina |first2=Priscilla |last3=Ajelli |first3=Marco |last4=Canale |first4=Angelo |last5=Dantas-Torres |first5=Filipe |last6=Otranto |first6=Domenico |last7=Benelli |first7=Giovanni |date=2025-01-09 |title=Human migrations, anthropogenic changes, and insect-borne diseases in Latin America |journal=Parasites & Vectors |volume=18 |issue=1 |pages=4 |doi=10.1186/s13071-024-06598-7 |doi-access=free |issn=1756-3305 |pmc=11721252 |pmid=39789650}}

• Environmental and Climate Change: Temperature, humidity, and rainfall changes affect the sandfly population. Rising temperatures have been linked to higher sandfly survival and breeding rates, allowing the disease to spread into higher altitudes and previously unaffected regions, such as Southern Europe and North America. Deforestation, urbanization, and dam construction disturb sandfly habitats, creating new transmission hotspots and increasing the risk of outbreaks.{{Cite journal |last1=Rupasinghe |first1=Ruwini |last2=Chomel |first2=Bruno B. |last3=Martínez-López |first3=Beatriz |date=2022-02-01 |title=Climate change and zoonoses: A review of the current status, knowledge gaps, and future trends |url=https://linkinghub.elsevier.com/retrieve/pii/S0001706X21004034 |journal=Acta Tropica |volume=226 |pages=106225 |doi=10.1016/j.actatropica.2021.106225 |pmid=34758355 |issn=0001-706X|doi-access=free }}

File:Leishmania 2009-04-14 smear.JPG

Leishmaniasis is diagnosed in the hematology laboratory by direct visualization of the amastigotes (Leishman–Donovan bodies). Buffy-coat preparations of peripheral blood or aspirates from marrow, spleen, lymph nodes, or skin lesions should be spread on a slide to make a thin smear and stained with Leishman stain or Giemsa stain (pH 7.2) for 20 minutes. Amastigotes are seen within blood and spleen monocytes or, less commonly, in circulating neutrophils and in aspirated tissue macrophages. They are small, round bodies 2–4 μm in diameter with indistinct cytoplasm, a nucleus, and a small, rod-shaped kinetoplast. Occasionally, amastigotes may be seen lying free between cells.{{cite book| last1 = Dacie | first1 = John V. | last2 = Bain | first2 = Barbara J. | first3 = Imelda | last3 = Bates |title=Dacie and Lewis practical hematology |publisher=Churchill Livingstone/Elsevier |location=Philadelphia |year=2006 |isbn=978-0-443-06660-3 }}{{Page needed|date=September 2010}} However, the retrieval of tissue samples is often painful for the patient and identification of the infected cells can be difficult. So, other indirect immunological methods of diagnosis are developed, including enzyme-linked immunosorbent assay, antigen-coated dipsticks, and direct agglutination test. Although these tests are readily available, they are not the standard diagnostic tests due to their insufficient sensitivity and specificity{{citation needed|date=May 2021}}.

Several different polymerase chain reaction (PCR) tests are available for the detection of Leishmania DNA. With this assay, a specific and sensitive diagnostic procedure is finally possible. The most sensitive PCR tests use minicircle kinetoplast DNA found in the parasite. Kinetoplast DNA contains sequences for mitochondrial proteins in its maxicircles (~25–50 per parasite), and guide RNA in its minicircles (~10,000 per parasite) of the kinetoplast. With this specific method, one can still detect Leishmania even with a very low parasite load. When needing to diagnose a specific species of Leishmania, as opposed to only detection, other PCR methods have been superior.{{cite journal | vauthors = Bensoussan E, Nasereddin A, Jonas F, Schnur LF, Jaffe CL | title = Comparison of PCR assays for diagnosis of cutaneous leishmaniasis | journal = Journal of Clinical Microbiology | volume = 44 | issue = 4 | pages = 1435–9 | date = April 2006 | pmid = 16597873 | pmc = 1448629 | doi = 10.1128/JCM.44.4.1435-1439.2006 }}

Most forms of the disease are transmitted only from nonhuman animals, but some can be spread between humans. Infections in humans are caused by about 21 of 30 species that infect mammals;{{cite web|url=https://www.cdc.gov/parasites/leishmaniasis/biology.html|title=Parasites – Leishmaniasis|date=January 2013|website=Centers for Disease Control and Prevention}} the different species look the same, but they can be differentiated by isoenzyme analysis, DNA sequence analysis, or monoclonal antibodies.

• Using insect repellent on exposed skin and under the ends of sleeves and pant legs. Follow the instructions on the label of the repellent. The most effective repellents generally are those that contain the chemical DEET (N,N-diethylmetatoluamide){{cite web|last=Prevention|first=CDC-Centers for Disease Control and|date=2020-02-19|title=CDC – Leishmaniasis – Prevention & Control|url=https://www.cdc.gov/parasites/leishmaniasis/prevent.html|access-date=2021-06-26|website=cdc.gov|language=en-us}}
• Leishmaniasis can be partly prevented by using nets treated with insecticide or insect repellent while sleeping. To provide good protection against sandflies, fine mesh sizes of 0.6 mm or less are required, but a mosquito net with 1.2mm mesh will provide a limited reduction in the number of sandfly bites. Finer mesh sizes have the downside of higher cost and reduced air circulation which can cause overheating. Many Phlebotomine sandfly attacks occur at sunset rather than at night, so it may also be useful to put nets over doors and windows or to use insect repellents.
• Use of insecticide-impregnated dog collars and treatment or culling of infected dogs.{{citation needed|date=January 2023}}
• Spraying houses and animal shelters with insecticides.* {{cite journal | vauthors = Alexander B, Maroli M | title = Control of phlebotomine sandflies | journal = Medical and Veterinary Entomology | volume = 17 | issue = 1 | pages = 1–18 | date = March 2003 | pmid = 12680919 | doi = 10.1046/j.1365-2915.2003.00420.x | s2cid = 31387956 | doi-access = free }}

• Prevention and control of leishmaniasis requires a multifaceted approach. Insecticide spraying, treated nets, and case management are commonly used strategies, while additional approaches are being explored for long-term disease control.
• Vector Control: Integrated Vector Management (IVM) approach is key to reducing sand fly populations. Some of the latest strategies include:
• Research is ongoing into genetically modifying sand flies to reduce their ability to transmit Leishmania parasites.{{Cite journal |last1=Kumari |first1=Yasoda |last2=Gunathilaka |first2=Nayana |last3=Amarasinghe |first3=Deepika |date=2025-01-27 |title=A comprehensive review of biological and genetic control approaches for leishmaniasis vector sand flies; emphasis towards promoting tools for integrated vector management |journal=PLOS Neglected Tropical Diseases |language=en |volume=19 |issue=1 |pages=e0012795 |doi=10.1371/journal.pntd.0012795 |doi-access=free |issn=1935-2735 |pmc=11771870 |pmid=39869587}}
• Attractive toxic sugar baits (ATSBs) attract and kill sand flies that feed on plant sugars.{{Cite book |title=Operational Manual on Leishmaniasis Vector Control, Surveillance, Monitoring and Evaluation |date=2023 |publisher=World Health Organization |isbn=978-92-4-006034-0 |edition=1st |location=Geneva}}
• Spatial repellents and insecticidal paint create long-term barriers against sand flies.
• Reservoir Control:
• Canine control measures: domestic dogs are major reservoirs for Leishmania infantum in regions where visceral leishmaniasis is common. Instead of widespread dog culling, which has been proven ineffective and controversial, deltamethrin-impregnated dog collars have been introduced as a safer and more effective alternative.{{Cite journal |last1=Halbig |first1=P. |last2=Hodjati |first2=M. H. |last3=Mazloumi-Gavgani |first3=A. S. |last4=Mohite |first4=H. |last5=Davies |first5=C. R. |date=2000 |title=Further evidence that deltamethrin-impregnated collars protect domestic dogs from sandfly bites |url=https://resjournals.onlinelibrary.wiley.com/doi/10.1046/j.1365-2915.2000.00229.x |journal=Medical and Veterinary Entomology |language=en |volume=14 |issue=2 |pages=223–226 |doi=10.1046/j.1365-2915.2000.00229.x |pmid=10872869 |issn=1365-2915|url-access=subscription }}
• Wildlife reservoirs: Controlling wild animal reservoirs such as rodents, marsupials, sloths, and armadillos is more challenging due to conservation concerns.{{Cite journal |last1=Cosma |first1=Claudia |last2=Maia |first2=Carla |last3=Khan |first3=Nushrat |last4=Infantino |first4=Maria |last5=Del Riccio |first5=Marco |date=2024-10-28 |title=Leishmaniasis in Humans and Animals: A One Health Approach for Surveillance, Prevention and Control in a Changing World |journal=Tropical Medicine and Infectious Disease |language=en |volume=9 |issue=11 |pages=258 |doi=10.3390/tropicalmed9110258 |doi-access=free |issn=2414-6366 |pmc=11598728 |pmid=39591264}}

Vaccination: Canine vaccinations have been developed and are now being used in some regions to reduce transmission. Human vaccinations are in development, with several candidates in clinical trials assessing their potential for long-term immunity.{{Citation |last1=Coelho |first1=Eduardo A. F. |title=Vaccines for Canine Leishmaniasis |date=2023 |work=Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges : Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis |pages=281–306 |editor-last=Christodoulides |editor-first=Myron |url=https://link.springer.com/chapter/10.1007/978-3-031-24355-4_13 |access-date=2025-03-19 |place=Cham |publisher=Springer International Publishing |language=en |doi=10.1007/978-3-031-24355-4_13 |isbn=978-3-031-24355-4 |last2=Christodoulides |first2=Myron|url-access=subscription }}

File:Paromomycin structure.svg is an inexpensive (US$10) and effective treatment for leishmaniasis.]]

The treatment is determined by where the disease is acquired, the species of Leishmania, and the type of infection.

For visceral leishmaniasis in India, South America, and the Mediterranean, liposomal amphotericin B is the recommended treatment and is often used as a single dose.{{cite journal |vauthors=Sundar S, Chakravarty J |date=January 2013 |title=Leishmaniasis: an update of current pharmacotherapy |journal=Expert Opinion on Pharmacotherapy |volume=14 |issue=1 |pages=53–63 |doi=10.1517/14656566.2013.755515 |pmid=23256501 |s2cid=207479873}} Rates of cure with a single dose of amphotericin have been reported as 95%. In India, almost all infections are resistant to pentavalent antimonials. In Africa, a combination of pentavalent antimonials and paromomycin is recommended. These, however, can have significant side effects. Miltefosine, an oral medication, is effective against both visceral and cutaneous leishmaniasis.{{cite journal |vauthors=Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ |date=November 2012 |title=Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis |journal=The Journal of Antimicrobial Chemotherapy |volume=67 |issue=11 |pages=2576–97 |doi=10.1093/jac/dks275 |pmid=22833634 |doi-access=free}} Side effects are generally mild, though it can cause birth defects if taken within three months of getting pregnant. It does not appear to work for L. major or L. braziliensis. Trifluralin, a herbicide, is shown to be effective treatment as ointment, without hemolytic or cell-toxic side-effects.{{cite journal |last1=Esteves |first1=M. A. |last2=Fragiadaki |first2=I. |last3=Lopes |first3=R. |last4=Scoulica |first4=E. |last5=Cruz |first5=M. E. M. |title=Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents |journal=Bioorganic & Medicinal Chemistry |date=1 January 2010 |volume=18 |issue=1 |pages=274–281 |doi=10.1016/j.bmc.2009.10.059 |pmid=19926293 |url=https://www.sciencedirect.com/science/article/pii/S0968089609009948|url-access=subscription }}

Recent research in leishmaniasis treatment explores combination therapies, nanotechnology-based drugs, and immunotherapy. Combination treatments, such as liposomal amphotericin B (L-AmB) with miltefosine or paromomycin, have shown high cure rates for visceral leishmaniasis while reducing treatment time and side effects. The WHO recommends miltefosine-based combination therapy for specific cases of visceral leishmaniasis. Nanotechnology-based treatments, including lipid and metallic nanoparticles, improve drug delivery by targeting parasites more precisely and reducing toxicity. Immune-modulating therapies, such as interferon-gamma (IFN-γ), are under investigation for their potential in enhancing immune responses against Leishmania infections.

The evidence around the treatment of cutaneous leishmaniasis is poor. Several topical treatments may be used for cutaneous leishmaniasis. Which treatments are effective depends on the strain, with topical paromomycin effective for L. major, L. tropica, L. mexicana, L. panamensis, and L. braziliensis. Pentamidine is effective for L. guyanensis. Oral fluconazole or itraconazole appears effective in L. major and L. tropica. There is limited evidence to support the use of heat therapy in cutaneous leishmaniasis as of 2015.{{cite journal | vauthors = Von Stebut E | title = Leishmaniasis | journal = Journal of the German Society of Dermatology | volume = 13 | issue = 3 | pages = 191–200; quiz 201 | date = March 2015 | pmid = 25721626 | doi = 10.1111/ddg.12595 | s2cid = 221649492 }}

As of 2018, no studies have determined the effect of oral nutritional supplements on visceral leishmaniasis being treated with anti-leishmanial drug therapy.{{cite journal | vauthors = Custodio E, López-Alcalde J, Herrero M, Bouza C, Jimenez C, Storcksdieck Genannt Bonsmann S, Mouratidou T, López-Cuadrado T, Benito A, Alvar J | title = Nutritional supplements for patients being treated for active visceral leishmaniasis | journal = The Cochrane Database of Systematic Reviews | volume = 2018 | pages = CD012261 | date = March 2018 | issue = 3 | pmid = 29578237 | pmc = 6494195 | doi = 10.1002/14651858.CD012261.pub2 | collaboration = Cochrane Infectious Diseases Group }} For the reason, it is not known if nutritional supplements are ineffective (or effective). Further research including high quality randomized controlled trials are needed to determine if supplements are helpful and if so, at what dose, to help people with VL who are undergoing treatment with anti-leishmanial medications.

The Institute for OneWorld Health has reintroduced the drug paromomycin for the treatment of leishmaniasis, results which led to its approval as an orphan drug. The Drugs for Neglected Diseases Initiative is also actively facilitating the search for novel therapeutics. A treatment with paromomycin will cost about US$10. The drug had originally been identified in the 1950s but had been abandoned because it would not be profitable, as the disease mostly affects poor people.{{cite web |date=31 July 2006 |title=A Small Charity Takes the Reins in Fighting a Neglected Disease |url=https://www.nytimes.com/2006/07/31/health/31charity.html |archive-url=https://web.archive.org/web/20161220101801/http://www.nytimes.com/2006/07/31/health/31charity.html |archive-date=20 December 2016 |work=New York Times}} The Indian government approved paromomycin for sale in August 2006.{{cite web |title=Drug Program – Clinical Trial of Paromomycin |url=http://www.oneworldhealth.org/drug_program |url-status=usurped |archive-url=https://web.archive.org/web/20100606042359/http://www.oneworldhealth.org/drug_program |archive-date=6 June 2010 |access-date=10 February 2011 |publisher=Institute for OneWorld Health}}

By 2012 the World Health Organization had successfully negotiated with the manufacturers to achieve a reduced cost for liposomal amphotericin B, to US$18 a vial, but several vials are needed for treatment and it must be kept at a stable, cool temperature.

File:Parasite130072-fig1 Map of cutaneous leishmaniasis in North Africa.tif

File:Leishmaniasis world map - DALY - WHO2002.svg for leishmaniasis per 100,000 inhabitants{{Div col|small=yes|colwidth=10em}}

{{legend|#b3b3b3|no data}}

{{legend|#ffff65|less than 20}}

{{legend|#fff200|20–30}}

{{legend|#ffdc00|30–40}}

{{legend|#ffc600|40–50}}

{{legend|#ffb000|50–60}}

{{legend|#ff9a00|60–70}}

{{legend|#ff8400|70–80}}

{{legend|#ff6e00|80–100}}

{{legend|#ff5800|100–120}}

{{legend|#ff4200|120–150}}

{{legend|#ff2c00|150–200}}

{{legend|#cb0000|more than 200}}

{{div col end}}]]

Out of 200 countries and territories reporting to WHO, 97 countries and territories are endemic for leishmaniasis.{{cite web |title=Leishmaniasis: Situation and trends |url=https://www.who.int/gho/neglected_diseases/leishmaniasis/en/ |website=WHO Global Health Observatory |access-date=30 May 2018}} The settings in which leishmaniasis is found range from rainforests in Central and South America to deserts in western Asia and the Middle East. It affects as many as 12 million people worldwide.{{cite web | url = https://www.who.int/leishmaniasis/burden/magnitude/burden_magnitude/en/index.html | title = Leishmaniasis: Magnitude of the problem | archive-url = https://web.archive.org/web/20131026230723/http://www.who.int/leishmaniasis/burden/magnitude/burden_magnitude/en/index.html | archive-date=26 October 2013 | publisher = World Health Organization }} Leishmaniasis affect an estimated 700,000 to 1 million new cases annually, with over a billion people living in endemic areas at risk of infection.{{Cite web |title=Leishmaniasis |url=https://www.who.int/news-room/fact-sheets/detail/leishmaniasis |access-date=2025-03-19 |website=www.who.int |language=en}} Visceral Leishmaniasis is a fatal form with the potential for outbreak, causing, 50,000 to 90,000 cases worldwide each year. However only 25-45% are reported to the WHO. Cutaneous Leishmaniasis is the most common form with 600,000 to 1 million new cases each year yet only 200,000 are officially reported. It is most common in Afghanistan, Algeria, Brazil, Colombia, and Iran. Mucocutaneous Leishmaniasis is rarer with over 90% of cases occurring in Bolivia, Brazil, and Peru. The visceral form is most common in Bangladesh, Brazil, Ethiopia, India, and Sudan. In 2014, more than 90% of new cases reported to WHO occurred in six countries: Brazil, Ethiopia, India, Somalia, South Sudan and Sudan.{{cite web |title=Epidemiological situation: Epidemiology |url=https://www.who.int/leishmaniasis/burden/en/ |archive-url=https://web.archive.org/web/20040630170300/http://www.who.int/leishmaniasis/burden/en/ |url-status=dead |archive-date=30 June 2004 |website=World Health Organization |access-date=30 May 2018}} {{As of|2010|post=,}} it caused about 52,000 deaths, down from 87,000 in 1990.

Leishmaniasis is found through much of the Americas from northern Argentina to South Texas, though not in Uruguay or Chile, and has recently been shown to be spreading to North Texas and Oklahoma,{{cite web|url=http://www.dallasnews.com/sharedcontent/dws/dn/latestnews/stories/091507dnmetskin.d3fcc2e2.html |title=Dallas News: Rare, non-fatal skin disease found in N. Texans |access-date=2015-06-02 |url-status=dead |archive-url=https://web.archive.org/web/20091227070142/http://www.dallasnews.com/sharedcontent/dws/dn/latestnews/stories/091507dnmetskin.d3fcc2e2.html |archive-date=December 27, 2009 }}{{cite journal | vauthors = Clarke CF, Bradley KK, Wright JH, Glowicz J | title = Case report: Emergence of autochthonous cutaneous leishmaniasis in northeastern Texas and southeastern Oklahoma | journal = The American Journal of Tropical Medicine and Hygiene | volume = 88 | issue = 1 | pages = 157–61 | date = January 2013 | pmid = 23185078 | pmc = 3541728 | doi = 10.4269/ajtmh.2012.11-0717 }} and further expansion to the north may be facilitated by climate change as more habitat becomes suitable for vector and reservoir species for leishmaniasis.{{cite journal | vauthors = González C, Wang O, Strutz SE, González-Salazar C, Sánchez-Cordero V, Sarkar S | title = Climate change and risk of leishmaniasis in north america: predictions from ecological niche models of vector and reservoir species | journal = PLOS Neglected Tropical Diseases | volume = 4 | issue = 1 | pages = e585 | date = January 2010 | pmid = 20098495 | pmc = 2799657 | doi = 10.1371/journal.pntd.0000585 | veditors = Galvani AP | doi-access = free }} Leishmaniasis is also known as papalomoyo, papa lo moyo, úlcera de los chicleros, and chiclera in Latin America.{{cite web |url= http://www.almanaqueept.net/Publicaciones/1985/198525.pdf |title=Papalomoyo |access-date=2010-08-16 |url-status=dead |archive-url=https://web.archive.org/web/20110723012227/http://www.almanaqueept.net/Publicaciones/1985/198525.pdf |archive-date=2011-07-23 }} During 2004, an estimated 3,400 troops from the Colombian army, operating in the jungles near the south of the country (in particular around the Meta and Guaviare departments), were infected with leishmaniasis. Allegedly, a contributing factor was that many of the affected soldiers did not use the officially provided insect repellent because of its disturbing odor. Nearly 13,000 cases of the disease were recorded in all of Colombia throughout 2004, and about 360 new instances of the disease among soldiers had been reported in February 2005.{{cite web|url=http://www.serviciojesuitaarefugiados-vzla.org/informes/infront-feb2005.html |url-status=dead |archive-url=https://web.archive.org/web/20051110025422/http://www.serviciojesuitaarefugiados-vzla.org/informes/infront-feb2005.html |archive-date=10 November 2005 |title=Informes – Informe de Fronteras Febrero 2005 |publisher=Servicio Jesuita a Refugiados}}

The disease is found across much of Asia and in the Middle East. Within Afghanistan, leishmaniasis occurs commonly in Kabul, partly due to bad sanitation and waste left uncollected in streets, allowing parasite-spreading sand flies an environment they find favorable.{{cite web | url = http://english.aljazeera.net/NR/exeres/8A2BB5AC-A330-4AF3-8ABA-7177872EC80F.htm | work = Al Jazeera English | title = CENTRAL/S. ASIA – Kabul: A city in intensive care | archive-url = https://web.archive.org/web/20070618183239/http://english.aljazeera.net/NR/exeres/8A2BB5AC-A330-4AF3-8ABA-7177872EC80F.htm | archive-date = June 18, 2007 }}{{cite web| first = Robert | last = Birsel | date=May 7, 2007 |title=Disfiguring skin disease plagues Afghanistan |url=http://www.e-ariana.com/ariana/eariana.nsf/allDocs/3D54699903FBCF92872572D4004E8BA7?OpenDocument |agency=Reuters |work=e-Ariana |access-date=8 December 2015 |url-status=dead |archive-url=https://web.archive.org/web/20151210183201/http://www.e-ariana.com/ariana/eariana.nsf/allDocs/3D54699903FBCF92872572D4004E8BA7?OpenDocument |archive-date=10 December 2015 }} In Kabul, the number of people infected was estimated to be at least 200,000, and in three other towns (Herat, Kandahar, and Mazar-i-Sharif) about 70,000 more occurred, according to WHO figures from 2002.{{cite web| first = Robert | last = Birsel |date=June 28, 2002 |title=Disfiguring epidemic hits 270,000 Afghans |url=http://www.e-ariana.com/ariana/eariana.nsf/7eca40d3d348841987256b79007d1cb8/70a208df652a4ced87256c04004f922a?OpenDocument |agency=Reuters |work=e-Ariana |access-date=December 8, 2015 |url-status=dead |archive-url=https://web.archive.org/web/20151210213154/http://www.e-ariana.com/ariana/eariana.nsf/7eca40d3d348841987256b79007d1cb8/70a208df652a4ced87256c04004f922a?OpenDocument |archive-date=December 10, 2015 }}{{cite web|url=https://www.voanews.com/a/a-13-a-2002-06-28-2-who/392333.html|title=WHO Seeking Funds to Prevent Leishmaniasis Outbreak in Afghanistan|date=October 2009|website=voanews}} Kabul is estimated as the largest center of cutaneous leishmaniasis in the world, with around 67,500 cases as of 2004.{{cite web | url = https://www.who.int/mediacentre/news/releases/2004/pr55/en/index.html | title = World Health Organization action in Afghanistan aims to control debilitating leishmaniasis | archive-url = https://web.archive.org/web/20101026134647/http://www.who.int/mediacentre/news/releases/2004/pr55/en/index.html | archive-date = 26 October 2010 }} Africa, in particular, the East and North, is also home to cases of leishmaniasis. Leishmaniasis is considered endemic also in some parts of southern parts of western Europe and has spread towards the north in recent years.{{cite journal | vauthors = Medlock JM, Hansford KM, Van Bortel W, Zeller H, Alten B | title = A summary of the evidence for the change in European distribution of phlebotomine sand flies (Diptera: Psychodidae) of public health importance | journal = Journal of Vector Ecology | volume = 39 | issue = 1 | pages = 72–7 | date = June 2014 | pmid = 24820558 | doi = 10.1111/j.1948-7134.2014.12072.x | s2cid = 20645170 | doi-access = free }} For example, an outbreak of cutaneous and visceral leishmaniasis was reported from Madrid, Spain, between 2010 and 2012.{{cite journal | vauthors = Aguado M, Espinosa P, Romero-Maté A, Tardío JC, Córdoba S, Borbujo J | title = Outbreak of cutaneous leishmaniasis in Fuenlabrada, Madrid | journal = Actas Dermo-Sifiliograficas | volume = 104 | issue = 4 | pages = 334–42 | date = May 2013 | pmid = 23567452 | doi = 10.1016/j.adengl.2013.03.005 | doi-access = free }}

Leishmaniasis is mostly a disease of the developing world and is rarely known in the developed world outside a small number of cases, mostly in instances where troops are stationed away from their home countries. Leishmaniasis has been reported by U.S. troops stationed in Saudi Arabia and Iraq since the Gulf War of 1990, including visceral leishmaniasis.{{cite web|url=http://www.veteransforcommonsense.org/index.php/veterans-category-articles/1649-kelly-kennedy |publisher=Veterans for Common Sense |first=Kelly |last=Kennedy |date=30 March 2010 |title=VCS Advocacy in the News: VA May Designate 9 Infectious Diseases as Related to Gulf War |access-date=10 February 2011 |url-status=dead |archive-url=https://web.archive.org/web/20110213124549/http://www.veteransforcommonsense.org/index.php/veterans-category-articles/1649-kelly-kennedy |archive-date=13 February 2011 }}{{cite web | url = http://www.sptimes.com/2004/06/09/Business/Company_s_mesh_will_h.shtml | title = Business: Company's mesh will help troops beat 'Baghdad boils' | archive-url = https://web.archive.org/web/20050316065427/http://www.sptimes.com/2004/06/09/Business/Company_s_mesh_will_h.shtml | archive-date = 16 March 2005 }}{{cite web |url=http://www.pdhealth.mil/downloads/Leishmaniasis_exsu_16Mar042.pdf |title=Archived copy |access-date=2007-09-17 |url-status=dead |archive-url=https://web.archive.org/web/20071012192134/http://www.pdhealth.mil/downloads/Leishmaniasis_exsu_16Mar042.pdf |archive-date=12 October 2007 |df=dmy-all }}

In September 2005, the disease was contracted by at least four Dutch marines who were stationed in Mazar-i-Sharif, Afghanistan, and subsequently repatriated for treatment.{{cite book|title=Leishmaniasis: Biology, Control and New Approaches for Its Treatment| first1 = Saurabh | last1 = Bhatia | first2 = Divakar | last2 = Goli |publisher=CRC Press|year=2016|isbn=9781315341897}}{{cite journal | vauthors = van Thiel PP, Leenstra T, de Vries HJ, van der Sluis A, van Gool T, Krull AC, van Vugt M, de Vries PJ, Zeegelaar JE, Bart A, van der Meide WF, Schallig HD, Faber WR, Kager PA | title = Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment | journal = The American Journal of Tropical Medicine and Hygiene | volume = 83 | issue = 6 | pages = 1295–300 | date = December 2010 | pmid = 21118937 | pmc = 2990047 | doi = 10.4269/ajtmh.2010.10-0143 }}

File:JerichoButtons.jpg in the Middle East, known then locally as "Jericho buttons" for the frequency of cases near the ancient city of Jericho]]

Descriptions of conspicuous lesions similar to cutaneous leishmaniasis appear on tablets from King Ashurbanipal from the seventh century BCE, some of which may have derived from even earlier texts from 1500 to 2500 BCE. Persian physicians, including Avicenna in the 10th century CE, gave detailed descriptions of what was called balkh sore.

{{cite journal | vauthors = Cox FE | title = History of human parasitology | journal = Clinical Microbiology Reviews | volume = 15 | issue = 4 | pages = 595–612 | date = October 2002 | pmid = 12364371 | pmc = 126866 | doi = 10.1128/CMR.15.4.595-612.2002 | publisher = The Wellcome Trust | isbn = 978-1-869835-86-6 | df = dmy-all | oclc = 35161690 }} In 1756, Alexander Russell, after examining a Turkish patient, gave one of the most detailed clinical descriptions of the disease. Physicians in the Indian subcontinent would describe it as kala-azar (pronounced kālā āzār, the Urdu, Hindi, and Hindustani phrase for "black fever", kālā meaning black and āzār meaning fever or disease). In the Americas, evidence of the cutaneous form of the disease in Ecuador and Peru appears in pre-Inca pottery depicting skin lesions and deformed faces dating back to the first century CE. Some 15th- and 16th-century texts from the Inca period and from Spanish colonials mention "valley sickness", "Andean sickness", or "white leprosy", which are likely to be the cutaneous form.{{cite web | title = WHO: Leishmaniasis background information – a brief history of the disease | url =https://www.who.int/leishmaniasis/en/ | url-status = live | archive-url = https://web.archive.org/web/20140315040939/http://www.who.int/leishmaniasis/en/ | archive-date = 15 March 2014 | df = dmy-all }}

It remains unclear who first discovered the organism. David Douglas Cunningham, Surgeon Major of the British Indian army, may have seen it in 1885 without being able to relate it to the disease.

{{cite book| vauthors = Cunningham DD | title = On the presence of peculiar parasitic organisms in the tissue of a specimen of Delhi boil | publisher = Printed by the superintendent of government printing, India | series = Scientific memoirs officers Medical Sanitary Departments Government India | location =Calcutta | pages = 21–31| year = 1885 | oclc = 11826455 }}{{cite journal | vauthors = Cox FE | title = History of human parasitology | journal = Clinical Microbiology Reviews | volume = 15 | issue = 4 | pages = 595–612 | date = October 2002 | pmid = 12364371 | pmc = 126866 | doi = 10.1128/CMR.15.4.595-612.2002 }} Peter Borovsky, a Russian military surgeon working in Tashkent, conducted research into the etiology of "oriental sore", locally known as sart sore, and in 1898 published the first accurate description of the causative agent, correctly described the parasite's relation to host tissues and correctly referred it to the protozoa. However, because his results were published in Russian in a journal with low circulation, his results were not internationally acknowledged during his lifetime.{{cite journal| vauthors = Hoare CA | year = 1938 | title = Early discoveries regarding the parasite of oriental sore | journal = Transactions of the Royal Society of Tropical Medicine and Hygiene | volume = 32 | issue = 1 | pages = 67–92 | doi = 10.1016/S0035-9203(38)90097-5 }} In 1901, William Boog Leishman identified certain organisms in smears taken from the spleen of a patient who had died from "dum-dum fever" (Dum Dum is an area close to Calcutta) and proposed them to be trypanosomes, found for the first time in India.{{cite journal| vauthors = Leishman WB | year = 1903 | title = On the possibility of the occurrence of trypanomiasis in India | journal = The British Medical Journal| volume = 1 | issue = 2213 | pages = 1252–1254 | doi = 10.1136/bmj.1.2213.1252 | pmc = 2514706 }} A few months later, Captain Charles Donovan (1863–1951) confirmed the finding of what became known as Leishman-Donovan bodies in smears taken from people in Madras in southern India.{{cite journal| vauthors = Donovan C | year = 1903| title = Memoranda: On the possibility of the occurrence of trypanosomiasis in India | journal = The British Medical Journal}} But it was Ronald Ross who proposed that Leishman-Donovan bodies were the intracellular stages of a new parasite, which he named Leishmania donovani.{{cite journal | vauthors = Ross R | title = Further Notes on Leishman's Bodies | journal = British Medical Journal | volume = 2 | issue = 2239 | pages = 1401 | date = November 1903 | pmid = 20761210 | pmc = 2514909 | doi = 10.1136/bmj.2.2239.1401 }} The link with the disease kala-azar was first suggested by Charles Donovan, and was conclusively demonstrated by Charles Bentley's discovery of L. donovani in patients with kala-azar.{{cite journal| vauthors = Bentley CA | title =Telegram to R. Ross | date = 24 December 1903 | journal = Ross Archives | page = 47/157}} Transmission by the sandfly was hypothesized by Lionel Napier and Ernest Struthers at the School of Tropical Medicine at Calcutta and later proven by his colleagues.{{cite journal | title = Dr. L. Everard Napier | journal = The Indian Medical Gazette | volume = 78 | issue = 5 | pages = 252 | date = May 1943 | pmid = 29012190 | pmc = 5158438 }}{{cite journal|last=Gewurtz|first=Margo S. |date=2017-01-01|title=Transnationalism in Missionary Medicine: The Case of Kala-azar in China and India, 1909–1946|journal=Social Sciences and Missions|language=en|volume=30|issue=1–2|pages=30–43|doi=10.1163/18748945-03001001|issn=1874-8945}} The disease became a major problem for Allied troops fighting in Sicily during the Second World War; research by Leonard Goodwin then showed pentostam was an effective treatment.{{cite news|url=https://www.telegraph.co.uk/news/obituaries/4241645/Leonard-Goodwin.html|title=Leonard Goodwin – Telegraph|date=14 January 2009|publisher=The Daily Telegraph|access-date=2009-01-18|url-status=live|archive-url=https://web.archive.org/web/20090420055410/http://www.telegraph.co.uk/news/obituaries/4241645/Leonard-Goodwin.html|archive-date=20 April 2009|df=dmy-all}}

• Stigma and Psychological Effects: The cutaneous and mucocutaneous forms of leishmaniasis can cause visible scarring and disfigurement, leading to social stigma, discrimination, and emotional distress. In some communities, individuals with visible scarring may face social challenges, including barriers to employment, social activities, education, and marriage, due to the stigma surrounding the disease. As awareness grows, mental health support and community education programs are recognized as important disease management aspects.{{Cite journal |last1=Bennis |first1=Issam |last2=De Brouwere |first2=Vincent |last3=Belrhiti |first3=Zakaria |last4=Sahibi |first4=Hamid |last5=Boelaert |first5=Marleen |date=2018-03-15 |title=Psychosocial burden of localised cutaneous Leishmaniasis: a scoping review |journal=BMC Public Health |volume=18 |issue=1 |pages=358 |doi=10.1186/s12889-018-5260-9 |doi-access=free |issn=1471-2458 |pmc=5855994 |pmid=29544463}}
• Economic burden: The cost of diagnosis, treatment, and hospitalizations pose financial challenges, particularly in regions where access to free or subsidized treatment is limited. Patients may experience income loss due to illness, disability and long recovery time. In rural areas, leishmaniasis can impact livestock and working animals, contributing to economic challenges for agricultural and livestock-dependent communities.
• Cultural beliefs and traditional medicine: In some endemic areas, cultural beliefs regarding the cause of leishmaniasis, including supernatural or spiritual explanations, may influence healthcare-seeking behaviors, sometimes delaying access to medical treatment.{{Cite journal |last1=Ramdas |first1=Sahienshadebie |last2=and van der Geest |first2=Sjaak |date=2020-04-02 |title=Not-knowing and the proliferation of assumptions: local explanations of Cutaneous Leishmaniasis in Suriname |url=https://www.tandfonline.com/doi/full/10.1080/13648470.2019.1627654 |journal=Anthropology & Medicine |volume=27 |issue=2 |pages=144–159 |doi=10.1080/13648470.2019.1627654 |issn=1364-8470 |pmid=31373516|hdl=11245.1/95500069-4894-4615-b974-5c50c4c7d977 |hdl-access=free }}

{{Main|Leishmaniasis vaccine}}

File:Leishmania culture in hood 2.jpg working on L. major in a biocontainment hood]]

As of 2017, no leishmaniasis vaccine for humans was available.{{cite journal | vauthors = Srivastava S, Shankar P, Mishra J, Singh S | title = Possibilities and challenges for developing a successful vaccine for leishmaniasis | journal = Parasites & Vectors | volume = 9 | issue = 1 | pages = 277 | date = May 2016 | pmid = 27175732 | pmc = 4866332 | doi = 10.1186/s13071-016-1553-y | doi-access = free }} Research to produce a human vaccine is ongoing.{{cite journal | vauthors = Ghorbani M, Farhoudi R | title = Leishmaniasis in humans: drug or vaccine therapy? | journal = Drug Design, Development and Therapy | volume = 12 | pages = 25–40 | date = 2018 | pmid = 29317800 | doi = 10.2147/DDDT.S146521 | doi-access = free | pmc = 5743117 }}

Currently some effective leishmaniasis vaccines for dogs exist.{{cite journal | vauthors = Moafi M, Rezvan H, Sherkat R, Taleban R | title = Leishmania Vaccines Entered in Clinical Trials: A Review of Literature | journal = International Journal of Preventive Medicine | volume = 10 | pages = 95 | date = 2019 | pmid = 31360342 | pmc = 6592111 | doi = 10.4103/ijpvm.IJPVM_116_18 | doi-access = free }} There is also the consideration that public health practices can control or eliminate leishmaniasis without a vaccine. Pyrimidine–based drugs are being explored as anti-leishmanial compounds.{{cite journal |last1=Ramesh |first1=Deepthi |last2=Sarkar |first2=Deblina |last3=Joji |first3=Annu |last4=Singh |first4=Monica |last5=Mohanty |first5=Amaresh K. |last6=G. Vijayakumar |first6=Balaji |last7=Chatterjee |first7=Mitali |last8=Sriram |first8=Dharmarajan |last9=Muthuvel |first9=Suresh K. |last10=Kannan |first10=Tharanikkarasu |date=April 2022 |title=First-in-class pyrido[2,3- d ]pyrimidine-2,4(1 H ,3 H )-diones against leishmaniasis and tuberculosis: Rationale, in vitro, ex vivo studies and mechanistic insights |url=https://onlinelibrary.wiley.com/doi/10.1002/ardp.202100440 |journal=Archiv der Pharmazie |language=en |volume=355 |issue=4 |pages=2100440 |doi=10.1002/ardp.202100440 |pmid=35106845 |s2cid=246474821 |issn=0365-6233|url-access=subscription }}

• Canine vector-borne disease
• Tropical disease

{{clear}}

{{Reflist}}

{{offline|med}}

{{Commons category|Leishmaniasis}}

• [https://www.doctorswithoutborders.org/what-we-do/medical-issues/kala-azar Doctors Without Borders' Leishmaniasis Information Page]
• [https://www.cdc.gov/parasites/leishmaniasis/ CDC Leishmaniasis Page]

{{Medical condition classification and resources

| ICD10 = {{ICD10|B|55||b|50}}

| ICD9 = {{ICD9|085}}

| DiseasesDB = 3266

| DiseasesDB_mult = {{DiseasesDB2|29171}}

| MedlinePlus = 001386

| eMedicineSubj = emerg

| eMedicineTopic = 296

| MeshID = D007896

}}

{{Protozoal diseases}}

{{Portal bar|Medicine}}

{{Authority control}}

Category:Dog diseases

Category:Parasitic infestations, stings, and bites of the skin

Category:Tropical diseases

Category:Wikipedia medicine articles ready to translate

Category:Wikipedia infectious disease articles ready to translate

Category:Zoonoses